Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Leases (2022 - 2025)

Amylyx Pharmaceuticals has reported Leases over the past 4 years, most recently at $5.2 million for Q4 2025.

  • Quarterly results put Leases at $5.2 million for Q4 2025, up 192.55% from a year ago — trailing twelve months through Dec 2025 was $5.2 million (up 192.55% YoY), and the annual figure for FY2025 was $5.2 million, up 192.55%.
  • Leases for Q4 2025 was $5.2 million at Amylyx Pharmaceuticals, down from $5.5 million in the prior quarter.
  • Over the last five years, Leases for AMLX hit a ceiling of $6.8 million in Q1 2022 and a floor of $1.3 million in Q1 2025.
  • Median Leases over the past 4 years was $5.1 million (2023), compared with a mean of $4.6 million.
  • Peak annual rise in Leases hit 192.55% in 2025, while the deepest fall reached 61.38% in 2025.
  • Amylyx Pharmaceuticals' Leases stood at $5.5 million in 2022, then plummeted by 32.57% to $3.7 million in 2023, then plummeted by 52.46% to $1.8 million in 2024, then soared by 192.55% to $5.2 million in 2025.
  • The last three reported values for Leases were $5.2 million (Q4 2025), $5.5 million (Q3 2025), and $5.8 million (Q2 2025) per Business Quant data.